Nexalin Technology, Inc. Common Stock (NXL) is a publicly traded Healthcare sector company. As of November 17, 2026, NXL trades at $1.54 with a market cap of $1.93M and a P/E ratio of -11.42. NXL moved +0.00% today. Year to date, NXL is -92.11%; over the trailing twelve months it is -95.32%. Its 52-week range spans $1.31 to $69.30. Analyst consensus is buy with an average price target of $15.00. Rallies surfaces NXL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Nexalin regains Nasdaq bid-price compliance; $2.5 million equity threshold remains: Nexalin regained compliance with Nasdaq’s $1.00 minimum bid-price rule after closing above that level for 21 consecutive sessions from Aug. 31 to Sept. 29, 2026. A Nasdaq Hearings Panel granted continued listing, subject to meeting other requirements, including a $2.5 million stockholders’ equity threshold by Jan. 4, 2027.
| Metric | Value |
|---|---|
| Price | $1.54 |
| Market Cap | $1.93M |
| P/E Ratio | -11.42 |
| EPS | $-0.48 |
| Dividend Yield | 0.31% |
| 52-Week High | $69.30 |
| 52-Week Low | $1.31 |
| Volume | 6.86K |
| Avg Volume | 0 |
| Revenue (TTM) | $217.16K |
| Net Income | $-8.99M |
| Gross Margin | 86.16% |
1 analysts cover NXL: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.00.